Details

Interviewer:
Tom Salemi
Content Director
Healthegy

Interviewee:
Vince Anido
Chairman and CEO
Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc. didn’t quite enjoy the “roller coaster ride” that followed the disappointing results of Rocket 1, a trial testing Rhopressa, a potential treatment for glaucoma. But CEO Vince Anido explains how the company regained its momentum quickly and why 2016 promises to be a big year.

Vicente Anido, Jr., PhD has served CEO since July 2013. He is the former president and chief executive officer of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. From 1996 to 1999, Anido led CombiChem, Inc., a drug discovery company.

In this interview, Anido explains how Aerie has endured a wild ride. He also shares the companies expectations for 2016.

To hear from more ophthalmology leaders register for the Ophthalmology Innovation Summit

Home

Interview Index:
1:24 – How Aerie has faired after the Rocket 1 clinical trial `Roller Coaster Ride.’
2:00 – How did Rocket 1 impacted Rocket 2 trial.
2:55 – “The FDA was actually encouraging us to not give up on Rocket 1.”
3:30 – Aerie already had put $10 million toward Rocket 4.
4:36 – Welcome to the “kindler, gentler” FDA?
6:11 – Critical to get support of the “process side” of the FDA.
6:43 – “This is a big year for us.”
7:06 – Will unveil the 12-month safety data on the 100 patients
7:21 – Plans to launch second Roclatan study, Mercury 2, this quarter.
7:35 – Now have three big trials going on in glaucoma, each with 55-60 different sites.
8:32 – Planning to file NDA for Rhopressa in the third quarter.
8:52 – “There are a lot of folks out there who believe that if Rhopressa is going to be a big drug, Roclatan is going to be a monster drug.”
9:52 – “Our cash balance at the end of this year is no different than the cash balance at the end of last year.”
10:08 – How Aerie raised $50 million from public investors last year.
11:02 – What keeps Vince Anido up at night?
13:00 – Can Aerie fill any vacuum created by consolidation of Mega-mergers?